Abstract: An anxiolytic composition includes a synergistic combination of one or more of an L-theanine, an s-adenosylmethionine (SAMe), and optionally an extract of Magnolia, an extract of Phellodendron, and a whey protein.

Abstract: An anxiolytic composition formulated for oral administration to a mammal includes a synergistic combination of L-theanine, at least one of magnolia and an extract of magnolia, and at least one of phellodendron and an extract of phellodendron. The composition may include a combination of an extract of Magnolia officinalis and a extract of Phellodendron amurense. The synergistic combination may provide an anxiolytic change in a release pattern of one or more brain neurotransmitters, such as glutamate and/or ?-aminobutyric acid (GABA).

Abstract: Compositions are described including a synergistic combination of hydroxytyrosol and 3-O-acetyl-11-keto-?-boswellic acid. The hydroxytyrosol may be sourced from an olive extract and the 3-O-acetyl-11-keto-?-boswellic acid may be sourced from a Boswellia serrata extract. The compositions may be formulated for oral administration to a mammalian or an avian subject. Methods for treating, repairing, or reducing damage to connective tissue caused by one or more inflammatory mediators and for reducing levels of one or more inflammatory mediators in connective tissue are provided, the methods comprising orally administering the compositions to a subject in need thereof.

Abstract: Compositions are described including a combination of hydroxytyrosol and 3-O-acetyl-11-keto-?-boswellic acid. The hydroxytyrosol may be sourced from an olive extract and the 3-O-acetyl-11-keto-?-boswellic acid may be sourced from a Boswellia serrata extract. The compositions may be formulated for oral administration to a mammalian or an avian subject. Methods for preventing or reducing an inflammatory response in connective tissue are provided, the methods comprising orally administering the compositions to a subject in need thereof.

Abstract: An extensibility model is used to provide active and interactive functionality in communication items, but the embodiments are not so limited. A computer system of an embodiment includes components configured to identify one or more activation triggers that operate to activate gadget code using an isolated code execution environment as part of injecting content into an email communication. A method of one embodiment provides an extensibility framework for using defined gadget triggers and associated gadget functionality as part of automatically injecting content inline with a mail message.

Abstract: Activating an extension includes opening a first compose application by a first computing device. A composed document is received, and an extension is activated in response to the document. The extension may be activated as the document is being composed.

Abstract: An anxiolytic composition includes a synergistic combination of one or more of an L-theanine, an s-adenosylmethionine (SAMe), and optionally an extract of Magnolia, an extract of Phellodendron, and a whey protein.

Abstract: An anxiolytic composition includes a synergistic combination of an L-theanine and a whey protein composition.

Abstract: Application extension management may be provided. Upon logging into a user device by a user, a list of a plurality of extensions associated with the user may be retrieved from a central repository. Access to each of the plurality of extensions associated with the user on the user device may then be provided to the user device.

Abstract: Application extension management may be provided. A plurality of related documents may be scanned to determine whether an activation trigger associated with an application extension has been triggered. In response to determining that the activation trigger associated with the application extension has been triggered, the application extension may be triggered and a user interface element associated with the application extension may be displayed according to a display rule.

Abstract: A compose form for drafting a message is presented inline within a window along with a message list. For example, instead of overlaying the message application's user interface (UI) with a new window for composing a message, the compose form is displayed within a portion of the window reserved for viewing content of messages. While composing the message using the compose form, the rest of the message application's UI remains visible and accessible to the user. For example, the user may navigate to another folder and/or move to another message/conversation by interacting with the tree view/message list view. A draft of the message being composed may be automatically saved when the user navigates away from the compose form (e.g. by selecting another conversation in the list view).

Abstract: Compositions are described including a synergistic combination of hydroxytyrosol and 3-O-acetyl-11-keto-?-boswellic acid. The hydroxytyrosol may be sourced from an olive extract and the 3-O-acetyl-11-keto-?-boswellic acid may be sourced from a Boswellia serrata extract. The compositions may be formulated for oral administration to a mammalian or an avian subject. Methods for treating, repairing, or reducing damage to connective tissue caused by one or more inflammatory mediators and for reducing levels of one or more inflammatory mediators in connective tissue are provided, the methods comprising orally administering the compositions to a subject in need thereof.

Abstract: Compositions are described including a combination of hydroxytyrosol and 3-O-acetyl-11-keto-?-boswellic acid. The hydroxytyrosol may be sourced from an olive extract and the 3-O-acetyl-11-keto-?-boswellic acid may be sourced from a Boswellia serrata extract. The compositions may be formulated for oral administration to a mammalian or an avian subject. Methods for preventing or reducing an inflammatory response in connective tissue are provided, the methods comprising orally administering the compositions to a subject in need thereof.

Abstract: Systems, methods, and software disclosed herein facilitate draft reminders. In at least one implementation, a primary view of an information management application is rendered. In various scenarios the primary view may include primary items, such as emails, events, tasks, or other types of items. When a reminder view is invoked, draft items are identified to include in the reminder view. The reminder view is then rendered in an overlaid manner with respect to the primary view and includes the draft items.

Abstract: Application extension management may be provided. A plurality of related documents may be scanned to determine whether an activation trigger associated with an application extension has been triggered. In response to determining that the activation trigger associated with the application extension has been triggered, the application extension may be triggered and a user interface element associated with the application extension may be displayed according to a display rule.

Abstract: Application extension management may be provided. A plurality of related documents may be scanned to determine whether an activation trigger associated with an application extension has been triggered. In response to determining that the activation trigger associated with the application extension has been triggered, the application extension may be triggered and a user interface element associated with the application extension may be displayed according to a display rule.

Abstract: Extension activation may be provided. Upon receiving a new document associated with a plurality of related documents, extension trigger conditions may be evaluated. In response to determining that an extension trigger is satisfied, a user interface element associated with the extension trigger may be displayed.

Abstract: An anxiolytic composition includes a synergistic combination of one or more of an extract of magnolia, an extract of phellodendron, an L-theanine, a whey protein composition, and/or an s-adenosylmethionine (SAMe).

Abstract: Compositions are described including a synergistic combination of hydroxytyrosol and 3-O-acetyl-11-keto-?-boswellic acid. The hydroxytyrosol may be sourced from an olive extract and the 3-O-acetyl-11-keto-?-boswellic acid may be sourced from a Boswellia serrata extract. The compositions may be formulated for oral administration to a mammalian or an avian subject. Methods for treating, repairing, or reducing damage to connective tissue caused by one or more inflammatory mediators and for reducing levels of one or more inflammatory mediators in connective tissue are provided, the methods comprising orally administering the compositions to a subject in need thereof.

Abstract: Compositions are described including a synergistic combination of hydroxytyrosol and 3-O-acetyl-11-keto-?-boswellic acid. The hydroxytyrosol may be sourced from an olive extract and the 3-O-acetyl-11-keto-?-boswellic acid may be sourced from a Boswellia serrata extract. The compositions may be formulated for oral administration to a mammalian or an avian subject. Methods for treating, repairing, or reducing damage to connective tissue caused by one or more inflammatory mediators and for reducing levels of one or more inflammatory mediators in connective tissue are provided, the methods comprising orally administering the compositions to a subject in need thereof.